



HELPING DELIVER LIFE-CHANGING THERAPIES



GLOBAL SITE
AND PATIENT SOLUTION

AN INNOVATIVE APPROACH TO DELIVERING A GLOBAL SITE AND PATIENT SOLUTION

Accelerating study startup is critical to reducing the time and cost of drug development. The stakes are highest for patients—those participating in clinical trials and those awaiting new therapies they generate. With this in mind, PPD offers an industry-altering site and patient solution—a new approach that puts the patient at the center of startup. We have fine-tuned startup objectives, expanded resources and realigned our expertise and operations to create this startup model.

Our site and patient solution incorporates the patient perspective into clinical innovation, study feasibility and protocol design, site selection and activation to optimize patient participation and follow-on research efficiencies.


STRATEGIC FEASIBILITY

GLOBAL SITE INTELLIGENCE & ACTIVATIONS

CLINICAL INNOVATION

SITE NETWORKS & PATIENT CENTRICITY

ACCELERATED ENROLLMENT SOLUTIONS





HARNESSING INNOVATION TO ADVANCE STUDY STARTUP

Our leadership in sites and patients is driven by innovation. PPD's clinical innovation team initiates, develops and implements pilots and projects with a specific focus on helping deliver more patients to fewer sites. Our team is also continuously enhancing PPD's decentralized clinical trial capabilities and use of mobile platforms.

Engaging and empowering clinical research participants, their caregivers and study sites improves retention and research outcomes. PPD has built patient-centric trial capabilities to bring the trial closer to the patient and achieve this engagement and empowerment.

Engaging
with patient
advocacy
groups



Creating a patient
reimbursement
strategy based
on the patient
population



Concierge
services to
provide
support for trial
comprehension,
participation logistics
and technologies



Distributing
patient
education
materials and
offering
follow-up
services



BUILDING A MORE DATA-DRIVEN STRATEGIC FEASIBILITY MODEL

The ability to predict site performance is critical to PPD's site selection process. We do not rely on the traditional approach of counting site enrollment estimates to match recruitment targets. We harness big data and conduct predictive modeling to identify the number of high-performing sites to engage for a study.

Our feasibility team knows that no single data source will provide all the answers, so our platforms bring together data from patient, investigator and site perspectives to inform our recommendations. We are not bound to

any one data source, giving us the flexibility to develop the solution that best meets your needs. PPD leverages our internal investigator, clinical trial and laboratory data, as well as external data from de-identified patient data sets, our site networks, electronic medical/health records and claims data platforms.

The rapid and predictable services delivered by our recruitment engine can increase sites' enrollment performance without adding sites or time. Typically, our solution provides 30 to 40 percent of the required patients.

DRIVING THE RIGHT PATIENTS TO THE RIGHT SITES



Our Accelerated Enrollment Solutions business focuses on maximizing patient delivery through highly accelerated and predictive centralized recruitment with the ability to provide patient enrollment at better than two times the industry average.

PPD has strategic relationships with site networks across the globe, providing access to more than 130 million patients and high-performing sites. Leveraging these partnerships allows for efficient study startup and execution through a master document repository and streamlined contracting.

PPD works to bring patient perspectives to study design, resulting in improved patient experience, engagement and retention. We are improving study quality and efficiency by incorporating the patient's perspective into the research process and experience. We've seen how involving patients in study design can improve protocol compliance, subject retention and overall study outcomes.



Synexus, a global site network of more than 180 dedicated and affiliate sites and access to 100 million U.S. households



Global Phase I site network of more than 30 sites in the U.S., Europe, Middle East, Africa and Asia-Pacific



PPD's early phase oncology network (EPON) of more than 30 global oncology sites



PPD® Select, PPD's top-performing sites based on recruitment and quality



PPD's pediatric investigator network (PIN) with key opinion leaders (KOL) and access to a large pediatric patient population

- Historical patient data analysis and direct feedback from patients
- Engagement with influential patient advocacy groups
- Optimized patient communication and connection, including e-consent, reminder apps and social media messaging
- Meaningful involvement of the patient voice in protocol design
- Home trial support conducted by in-country national teams experienced in home care
- Transparent study results for patients

CHANGING THE GAME: STARTUP COORDINATION AND CONSISTENCY WORLDWIDE



To address the rising costs of drug development, PPD is focused on greater global harmonization and planning across development functions. Our site activation services have evolved over the past five years to increase global coordination and consistency, so sites can enroll patients sooner and trials adhere to timelines.

Our global site intelligence and activation (SIA) team works to improve cycle times by coordinating and planning startup activities across global study sites. Working in tandem with the clinical innovation group, the SIA team drives improvements by focusing on local country regulatory submissions by region, global site contracts and budgets, and setup activities for the clinical trial management system (CTMS).

ACCELERATED ENROLLMENT SOLUTIONS

Our commitment to innovation is strengthened by our Accelerated Enrollment Solutions business, which helps deliver site and enrollment solutions through Synexus, Acurian and Optimal Research. Through Accelerated Enrollment Solutions, we deliver proven approaches, including PatientAdvantage and the just-in-time oncology enrollment enhancement solution provided through Optimal Research.

Together we can improve the inefficiencies and challenges of study startup to shorten timelines and lower the costs of clinical research.



PatientAdvantage— A New Way of Thinking about Clinical Development and Delivery

PPD has built a patient-centered, innovative model that delivers enrollment and budget certainty, speed, cost savings and increased data quality by removing inefficiencies and unknowns in patient enrollment and site selection.

PatientAdvantage changes traditional enrollment planning and feasibility allowing us to recruit qualified patients directly from the general population with less reliance on site-acquired patients.

Oncology Enrollment Enhancement— Your first patient in, faster.

With 40 percent of ongoing oncology studies failing to achieve patient enrollment*, new recruitment methods are needed to help patients receive the life-saving therapies they require. Leveraging a just-in-time enrollment model, PPD is helping bend the cost-time curve of oncology drug development. This enrollment enhancement solution utilizes a U.S. site management network of approximately 250+ clinical sites and 1,000+ investigators with expertise in oncology. Because of this unique approach, the model aims to significantly reduce cycle times to first patient enrolled for certain oncology studies by nearly 50 percent, frequently initiating a site within 14 days from a patient being identified.



For more information, please contact us at
+1 877 643 8773 or +1 919 456 5600

ppdi.com/sitesandpatients



twitter.com/PPDCRO



facebook.com/PPDCRO



youtube.com/PPDCRO



plus.google.com/+PPDCRO



linkedin.com/company/ppd